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Abstract
This study examines whether tobacco dependence severity moderates the acute effects of reducing 
nicotine content in cigarettes on the addiction potential of smoking, craving/withdrawal, or 
smoking topography. Participants (N = 169) were daily smokers with mild, moderate, or high 
tobacco-dependence severity using the Heaviness of Smoking Index. Following brief abstinence, 
participants smoked research cigarettes varying in nicotine content (0.4, 2.4, 5.2, 15.8 mg 
nicotine/g tobacco) in a within-subject design. Results were analyzed using repeated measures 
analysis of co-variance. No main effects of dependence severity or interactions with nicotine dose 
were noted in relative reinforcing effects in concurrent choice testing or subjective effects on the 
modified Cigarette Evaluation Questionnaire. Demand for smoking in the Cigarette Purchase Task 
was greater among more dependent smokers, but reducing nicotine content decreased demand 
independent of dependence severity. Dependence severity did not significantly alter response to 
reduced nicotine content cigarettes on the Minnesota Tobacco Withdrawal Scale nor Questionnaire 
of Smoking Urges-brief (QSU) Factor-2 scale; dependence severity and dose interacted 
significantly on the QSU-brief Factor-1 scale, with reductions dependent on dose among highly 
but not mildly or moderately dependent smokers. Dependence severity and dose interacted 
significantly on only one of six measures of smoking topography (i.e., maximum flow rate), which 
increased as dose increased among mildly and moderately but not highly dependent smokers. 
These results suggest that dependence severity has no moderating influence on the ability of 
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reduced nicotine content cigarettes to lower the addiction potential of smoking, and minimal 
effects on relief from craving/withdrawal or smoking topography.
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1. Introduction
Tobacco dependence severity is a robust predictor of success in quitting cigarette smoking 
(Baker et al., 2017; Borland et al., 2010; Kurti et al., 2016; Mercincavage et al., 2013; 
Vangeli et al., 2011). Indeed, two specific measures of dependence severity, the number of 
cigarettes smoked per day (CPD) and time to first cigarette upon waking, have broad 
generality in predicting initiation and maintenance of smoking cessation and have been 
validated in clinical samples and self-quitters (Baker et al., 2017; Borland et al., 2010; Kurti 
et al., 2016; Mercincavage et al., 2013; Vangeli et al., 2011). The Heaviness of Smoking 
Index (HSI, Heatherton et al., 1989) combines these two markers with comparable or greater 
predictive validity than either individual item alone (e.g., Borland et al., 2010; Kurti et al., 
2016; Schnoll et al., 2013). The brevity and associated lower participant burden of the HSI is 
another notable practical advantage of that instrument (Schnoll et al., 2013).
The primary purpose of the present study is to examine whether individual differences in 
dependence severity as measured by the HSI moderate response to reduced nicotine content 
cigarettes. On July 28, 2017, Scott Gottlieb, MD, Commissioner of the U.S. Food and Drug 
Administration (FDA), announced a new regulatory plan to reduce the adverse impact of 
cigarette smoking on U.S. public health. That plan includes consideration of a policy to 
reduce the maximal nicotine content in cigarettes in order to lower their addiction potential 
(U.S. Food and Drug Administration, 2017). There is overwhelming scientific evidence that 
nicotine is the constituent in cigarette smoke that promotes dependence or addiction (U.S. 
Department of Health and Human Services (US DHHS), 1988; U.S. DHHS, 2014). The 
rationale behind reducing the nicotine content of cigarettes is to (a) lower the dependence 
severity of current smokers thereby making it easier for them to quit should they choose to 
do so and (b) reduce the likelihood that those who experiment with smoking will develop 
dependence (Benowitz and Henningfield, 1994).
The 2009 Family Smoking Prevention and Tobacco Control Act (FSPTCA) granted the FDA 
regulatory authority over cigarettes and other tobacco products (Family Smoking Prevention 
and Tobacco Control Act (H.R. 1256) (2009)). That legislation includes authority to 
establish a standard to reduce the maximal nicotine content of cigarettes if doing so benefits 
public health. Knowing whether reducing the nicotine content of cigarettes reduces the 
addiction potential of smoking even among more dependent smokers is important in 
assessing the potential impact that such a policy may have on existing smokers. Other 
important questions to examine are whether reduced nicotine content cigarettes adequately 
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reduce withdrawal and craving and whether they may prompt compensatory smoking in 
more severely dependent smokers (Keith et al., 2017; US DHHS, 2001, 2010).
Results from controlled studies of reduced nicotine content cigarettes among psychiatrically 
and socioeconomically stable, healthy smokers have been promising, with extended 
exposure to these cigarettes producing significant reductions in CPD and nicotine 
dependence, and increases in quit attempts with little evidence of compensatory smoking 
(Benowitz et al., 2012; Donny et al., 2015; Hatsukami et al., 2010; Hatsukami et al., 2013a, 
2013b). More recently, studies of reduced nicotine content cigarettes have been initiated in 
populations especially vulnerable to smoking and dependence, including individuals with 
psychiatric conditions or socioeconomic disadvantage (AhnAllen et al., 2015; Faulkner et 
al., 2017; Higgins et al., 2016, 2017; Tidey et al., 2013, 2016, 2017). These studies have 
mostly although not exclusively (Tidey et al., 2017) examined acute exposure. Again results 
are encouraging, with reduced nicotine content cigarettes producing weaker relative 
reinforcing and positive subjective effects, key markers of addiction potential, while also 
providing significant relief from withdrawal and craving, and no evidence of compensatory 
smoking.
To our knowledge, there is only a single report in this emerging literature examining whether 
tobacco dependence severity moderates response to reduced nicotine content cigarettes. That 
study examined acute response to varying doses of reduced nicotine content cigarettes 
following brief smoking abstinence among young adults, a population especially vulnerable 
to cigarette smoking and eventual dependence (Faulkner et al., 2017). Withdrawal and 
craving ratings were significantly greater among more dependent smokers prior to but not 
after smoking indicating that reduced nicotine content cigarettes reduced craving and 
withdrawal equally across doses. Dependence severity was not associated with subjective 
ratings of cigarette quality or sustained attention. More direct measures of addiction 
potential (e.g., reinforcing effects) were not assessed. The present study is a secondary 
analysis of a study that examined acute exposure to reduced nicotine content cigarettes in 
participants from three populations also especially vulnerable to cigarette smoking and 
dependence: individuals with affective disorders, individuals with opioid dependence, and 
socioeconomically disadvantaged women of reproductive age (Higgins et al., 2017). The 
study explicitly focused on assessing addiction potential, noting that reducing nicotine 
content dose-dependently decreased the addiction potential of smoking in these vulnerable 
populations (relative reinforcing and positive subjective effects) while reducing craving and 
withdrawal, with minimal differences between populations and no evidence of compensatory 
smoking. Higgins et al. (2017) did not examine any potential moderating influence of 
dependence severity. Considering that one-quarter or more of U.S. adult smokers are 
severely dependent on cigarette smoking (e.g., Schnoll et al., 2013), the present study is 
focused on that topic.
2. Methods
2.1. Study sample
Participants in this multisite study (University of Vermont, Brown University, Johns Hopkins 
University School of Medicine) included 169 adult daily smokers (56 with affective 
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disorders, 60 with opioid dependence, 53 socioeconomically disadvantaged women of 
reproductive age), who provided written informed consent. Participants from each 
population were studied at the University of Vermont; Brown University studied only those 
with affective disorders; Johns Hopkins University studied those with opioid dependence 
and disadvantaged women. Study inclusion and exclusion criteria have been reported 
previously (Higgins et al., 2017).
Instead of categorizing study participants by psychiatric condition or socioeconomic status 
in the present study, they were categorized by dependence severity. All study participants 
completed the Fagerstrom Test for Nicotine Dependence (FTND) (Heatherton et al., 1991) 
as well as a tobacco history questionnaire at study intake assessment. HSI scores were 
calculated by summing scores from items 1 and 4 of the FTND. Possible HSI scores range 
from 0 to 6. Using HSI cut-points previously established in a U.S. nationally representative 
sample of current smokers (Schnoll et al., 2013), participants with scores of 0–2, 3, and 4–6 
were categorized as mildly, moderately, and highly dependent, respectively. These 
dependence severity categories are associated with different sociodemographics, health 
outcomes, quality of life, productivity, and health care utilization characteristics (Schnoll et 
al., 2013). Prior research comparing HSI scores treated as a categorical variable show them 
to be comparable in predictive utility to treating scores as a continuous variable (Borland et 
al., 2010).
2.2. Research cigarettes
This study used Spectrum research cigarettes manufactured by 22nd Century Group 
(Clarence, NY) and obtained from the National Institute on Drug Abuse. Four nicotine doses 
were investigated with nicotine content averaged across menthol and non-menthol products 
(assignment of a menthol or non-menthol product was based on a participant’s usual brand): 
15.8, 5.2, 2.4, and 0.4 mg of nicotine per gram of tobacco (mg/g). The 15.8 mg/g dose 
served as a control for nicotine levels typical of commercial cigarettes. All sessions were 
conducted under double-blind conditions.
2.3. Procedure
These procedures have been described previously (Higgins et al., 2017). Briefly, participants 
completed fourteen 2–4 h sessions in a within-subjects design. Participants abstained from 
smoking for 6–8 h prior to sessions. Sessions were organized into three phases. In Phase 1 
(Sessions 1–5), participants sampled the research cigarettes under double-blind conditions 
with cigarettes identified by arbitrary letter codes. Participants were oriented to the research 
protocol in Session 1 using their usual-brand cigarette. In Sessions 2–5 participants smoked 
one research cigarette per session. Participants smoked the research cigarettes ad lib using a 
plastic cigarette holder connected to a device that recorded smoking topography (Clinical 
Research Support System, CReSS; Lee et al., 2003). After smoking the assigned cigarette 
each session, participants completed the Cigarette Purchase Task (CPT), a behavioral 
economic simulation task that has participants estimate the number of cigarettes they would 
anticipate smoking in a 24-hour period across a wide range of cigarette prices; those 
estimates are used to model (1) participant cigarette smoking rate when unconstrained by 
cost (Intensity), (2) maximal amount of money one is willing to spend on daily smoking 
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(Omax), (3) the price at which smoking rate begins decreasing proportionate to increasing 
price (Pmax), (4) the price at which one would quit smoking rather than incur the cost 
(Breakpoint), and (5) overall sensitivity of demand to price (Alpha) (Jacobs and Bickel, 
1999; MacKillop et al., 2008). Participants also completed the modified Cigarette Evaluation 
Questionnaire (mCEQ) (Cappelleri et al., 2007) once prior to and immediately after 
smoking, and the Minnesota Tobacco Withdrawal Scale (MTWS) (Hughes and Hatsukami, 
1986) and Questionnaire of Smoking Urges-brief scale (QSU-brief) (Cox et al., 2001) 
administered prior to and every 15 min for 60 min after smoking. Phase 2 (Sessions 6–11) 
directly tested the relative reinforcing effects of the different dose cigarettes by allowing 
participants to choose which cigarette they preferred to smoke in two-choice concurrent test 
sessions (Lussier et al., 2005; Johnson et al., 2004). Each of the six possible cigarette dose-
pair combinations was tested once in separate sessions. In these 3-hour sessions, a 
participant sat alone in a comfortable, ventilated room. When they wished to smoke, they 
used a computer mouse to click on one of two icons on a screen representing the two 
cigarettes available that session. After ten clicks on the icon they could take two puffs of the 
associated cigarette (Lussier et al., 2005). Participants were free to choose either option as 
often as they wished or abstain. Lastly, Phase 3 (Sessions 12–14) used the same arrangement 
as Phase 2, but compared only the 0.4 and 15.8 g/mg doses. This phase assessed whether 
preference could be reliably shifted away from the high dose. Puffs from the low dose 
remained available by clicking that option 10 times while the number of clicks necessary to 
earn puffs from the highest dose started at 10 and increased each time it was chosen to 160, 
320, 640, 1280, 2400, 3600, 4800, 6000, 7200, and 8400 clicks (Sigmon et al., 2003).
2.4. Statistical methods
Analyses of Phase 1 results examined whether tobacco dependence severity (HSI) moderates 
the effect of dose on CPT, mCEQ and smoking topography by using repeated-measures 
analysis of covariance, with nicotine dose as the within-participant factor and HSI as a fixed 
effect with three levels. The comparison of HSI levels on demographic characteristics using 
Fisher’s Exact Test and the Wilcoxon Rank Sum Test found significant differences on age 
and level of education; therefore, they were included as covariates. Sex was also included as 
a covariate based on prior reports on male-female differences in response to reduced nicotine 
content cigarettes (Faulkner et al., 2018; Perkins and Karelitz, 2015). The MTWS, QSU-
Brief, and breath CO levels were examined similarly with time as another within-participant 
factor. To measure CO boost, pre-smoking CO values were subtracted from post-smoking 
CO values. Analyses also included fixed effects for (1) session and (2) the three primary 
study vulnerable populations who were studied in independent experiments using parallel 
research protocols and combined for analysis in the original and this secondary study. Time-
by-dose and HSI-by-dose interactions were included to test whether CO boost or subjective 
effects before and after smoking differed by dose and to test for differential effects of HSI by 
dose; when not significant, interaction effects were dropped from models. Because the 
research cigarettes were presented in random order using a Latin square design, sequence 
was included in the model as a random effect. An additional random effect was included to 
account for the three study sites. Significant main or interaction effects were followed by 
post hoc testing using Bonferroni corrections, dividing the critical value (p < .05) by the 
number of comparisons to derive a more conservative Type I error rate.
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Differences in preference among all possible dose pairs (Phase 2) were similarly examined 
using repeated-measures analysis of variance, with each pairwise combination as the within-
participant factor, HSI as a fixed effect, and education, age, and sex as covariates. 
Differences among participants in preference for the highest- vs lowest-dose cigarettes 
(Phase 3) were examined using a repeated-measures analysis of covariance, with session as 
the repeating factor, population and HSI as the between-subjects factors and education, age, 
and sex as covariates.
To describe aggregate-level cigarette demand on the CPT, demand curves were fit to mean 
reported consumption at each price across participants, doses, and HSI. To quantify 
participant-level CPT demand elasticity, a demand curve was fit to individual consumption 
at each price for each dose. When fitting demand curves, we constrained demand intensity to 
the participants’ reported consumption at $0.00 to leave elasticity as the only fitted 
parameter. Elasticity values > 1.00 were winsorized to 1.00 prior to statistical analysis (22 of 
845 cases). All other demand indices were empirically quantified from observed values. 
Omax, Pmax, Breakpoint, and Alpha were log10 transformed to correct for skewness. We 
reviewed CPT results and found systematic patterns in 92.7% of demand curves; no data 
were excluded from analyses. In cases where participants reported zero consumption across 
all prices (54 of 845 cases), curve fitting was not possible, so elasticity was not analyzed and 
other demand indices were quantified as 0.
Across all tests, statistical significance was defined as p < .05 (2-tailed). Significant main or 
interaction effects were followed by post hoc testing using Bonferroni corrections, dividing 
the critical value (p < .05) by the number of comparisons to derive a more conservative Type 




Approximately one third of participants fell into each dependence severity category (Table 
1). Distribution of participants from among the three populations initially recruited for this 
study did not differ significantly across dependence severity categories. Only two socio-
demographic characteristics differed significantly by dependence severity, with those with 
high dependence severity being older and less educated. As expected, more severely 
dependent participants smoked more cigarettes per day, had higher baseline breath CO 
levels, higher mean FTND total scores, and started smoking at a younger age.
3.2. Relative reinforcing effects of smoking
3.2.1. Direct testing—No significant differences by dependence severity were noted in 
how participants chose between the different dose cigarettes in concurrent choice testing. 
Participants chose the higher nicotine dose at significantly greater than chance levels across 
each of the 6 dose pairs independent of dependence severity (F[5835] = 6.12, p < .001) 
(Table 2). There were no significant interactions of dependence severity and nicotine dose.
Higgins et al. Page 6













When the 0.4 and 15.8 mg doses were retested in Phase 3 with the former still available at 
10 mouse clicks but the latter on a progressive ratio schedule, participants chose the 0.4 
mg/g dose significantly more than the 15.8 mg/g dose independent of dependence severity 
level (t (158) = 3.41, p < .001) (Table 3).
3.2.2. Simulation modeling—CPT demand varied by dependence severity and 
cigarette nicotine dose (Fig. 1, upper and lower panels, respectively). Regarding dependence 
severity, demand Intensity (F[2154] = 20.43, p < .001) and Omax (F[2157] = 3.96, p = .02) 
were greater among more dependent smokers (Table 4, upper panel); no significant 
differences by dependence severity were noted on Pmax, Breakpoint, or Alpha. Regarding 
dose effects, significant dose differences were discerned across each CPT index (Fs[3489] ≥ 
5.19, ps ≤ 0.002) except Alpha, with a general pattern of more intense and persistent demand 
at higher nicotine doses (Table 4, lower panel). No significant interactions of dependence 
severity and nicotine dose were noted.
3.3. Participant ratings
3.3.1. Modified Cigarette Evaluation Questionnaire—No significant differences by 
dependence severity were noted on any mCEQ subscale (Table 5, upper panel). Significant 
effects of nicotine dose were noted across mCEQ measures (Fs[3501] ≥ 7.08, ps < 0.001) 
(Table 5, lower panel), with mean scores increasing as a function of increasing nicotine dose. 
No significant interactions of dependence severity and nicotine dose were noted.
3.3.2. Minnesota Tobacco Withdrawal Scale—No significant differences by 
dependence severity were noted in MTWS total scores (Table 6, upper panel) nor any 
interactions involving dependence severity. There was a significant interaction of dose and 
time (F[12, 2014] = 2.64, p = .002) (Table 6, lower panel); each of the varying dose 
cigarettes decreased pre-smoking ratings with duration of effects greatest at the 15.8 mg/g 
dose.
There was a significant main effect of dependence severity (F [2156] = 5.60, p = .005) and 
an interaction of dose and time (F[12, 2014] = 5.86, p < .001) on the MTWS Desire-to-
Smoke item (Fig. 2). More severely dependent smokers reported a stronger desire to smoke. 
Each of the doses reduced ratings post-smoking, but the duration of effects was greater at the 
15.8 mg/g dose. There was no significant interaction of dependence severity and dose on this 
item.
3.3.3. Brief Questionnaire of Smoking Urges (QSU-brief)—There were significant 
interactions of dose and time (F[12, 2014] = 8.92, p < .0001) and dependence severity and 
dose (F [6495] = 2.32, p = .03) on Factor-1 ratings (i.e., urges associated with positive 
reinforcing effects) (Fig. 3, upper panel). More dependent smokers reported greater mean 
urges than less dependent smokers. The interaction of dose and time on this measure 
corresponds to the 15.8 mg/g dose having the longest duration of action. Lastly, the 
significant interaction of dependence severity and dose corresponds to each of the cigarettes 
producing comparable craving reductions among the mild and moderately but not the highly 
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dependent smokers with whom the 15.8 mg dose produced greater reductions than the lower 
doses.
Factor-2 ratings (i.e., urges associated with negative reinforcing effects) showed a similar 
pattern of significant effects of dependence severity (F[2153] = 3.45, p = .03) and interaction 
of dose and time (F [12, 2014] = 5.22, p < .001), but no significant interaction of dependence 
severity and dose (Fig. 3, bottom panel).
3.4. Smoking topography
There were no significant main effects of dependence severity noted in smoking topography. 
There were significant main effects of dose on three of the six measures (total puff volume, 
mean maximum flow rate, and puff number) (Fs[3488] ≥ 3.54, ps ≤ 0.01) (Table 7). The 
effects of dose were in the direction of larger, more intense, and greater number of puffs as a 
function of increasing nicotine dose, opposite of what is expected with compensatory 
smoking. There was a significant interaction of dependence severity and dose on mean 
maximum flow rate (F [6482] = 2.39, p = .03), where rates increased by dose among mildly 
and moderately but not highly dependent smokers (Fig. 4). Again, this effect was not 
suggestive of compensatory smoking.
There were no significant main effects of dependence severity or nicotine dose on breath CO 
levels across the 60 min of post-smoking monitoring (not shown). There was a significant 
effect of time (F [3504] = 104.46, p < .0001), with levels increasing from pre- to post-
smoking and then dissipating over time. No significant interactions between dependence 
severity, dose, or time were observed.
4. Discussion
The present results offer no evidence that the ability of reduced nicotine content cigarettes to 
lower the addiction potential of smoking is moderated by tobacco dependence severity. 
Reducing the nicotine content of cigarettes decreased the relative reinforcing effects of 
smoking independent of dependence severity, with convergent support for that conclusion 
across two measures (concurrent choice testing, CPT). Importantly, preference for higher 
over lower dose cigarettes could also be reversed by increasing response effort to obtain the 
former independent of dependence severity. Reducing nicotine content also decreased the 
positive subjective effects of smoking on the mCEQ independent of dependence severity 
consistent with lower addiction potential.
We saw minimal evidence that reducing the nicotine content of cigarettes would leave more 
severely dependent smokers with untoward levels of withdrawal or craving (Donny et al., 
2014; Hatsukami et al., 2013a, 2013b). Each of the cigarette doses investigated reduced 
MTWS total scores from pre-smoking levels. Those effects were larger in magnitude and of 
longer duration at the highest dose, but did not interact with dependence severity. Indeed, no 
differences by dependence severity were noted on MTWS total scores. That differs from 
results reported by Faulkner et al. (2017) who noted significant differences in withdrawal 
symptomology by dependence severity. Accounting for this between-study discrepancy is 
difficult as different instruments were used to assess withdrawal in the two studies and the 
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populations differed. The MNWS was used in the present study while the Shiffman-Jarvik 
Withdrawal scale (Shiffman and Jarvik, 1976) was used in the Faulkner et al. (2017, 2018) 
study, and they studied younger (mean age 22.3 + 2.2) smokers without comorbid 
psychiatric conditions while the present study examined older smokers (35.6 ± 11.4) and 
presence of a comorbid psychiatric condition was an inclusion criterion in two-thirds of the 
sample and not an exclusion criterion in the other third. The three measures used to assess 
craving in the present study all showed differences by dependence severity consistent with 
what Faulkner et al. reported. For two of those measures (MTWS Desire-to-Smoke item and 
QSU-brief Factor 2) there were no significant dose differences in the ability of smoking to 
decrease craving across the different levels of dependence severity consistent with the 
pattern reported by Faulkner et al. The exception to that pattern was observed on the QSU-
brief Factor 1 scale, where each of the doses decreased craving comparably among those 
with mild and moderate dependence severity while effects were dose-dependent among 
highly dependent smokers. That observation suggests that reducing the nicotine content of 
cigarettes below current commercial levels could impact highly dependent smokers more 
than moderately or mildly dependent smokers in terms of experiencing greater craving. This 
interaction of dependence severity and nicotine content was not reported by Faulkner et al. 
perhaps suggesting that this may be an effect specific to older, more dependent smokers. 
This interaction of dependence severity and dose in the present study was only observed on 
the QSU Factor 1 subscale that focuses specifically on craving for the positive reinforcing 
effects of smoking suggesting that dimension is more sensitive to differences by dependence 
severity.
Regarding the potential of reduced content cigarettes engendering compensatory smoking in 
more severely dependent smokers, we saw no evidence supporting that concern in the 
present study. Indeed, in the only interaction of dependence severity and dose observed on a 
measure of smoking topography, mildly and moderately dependent smokers responded in a 
manner opposite of what occurs with compensatory smoking (i.e., they smoked the lower 
content cigarettes less intensively) while highly dependent smokers showed no differences in 
smoking intensity by nicotine content level.
A secondary aim of this study was to advance knowledge about potential differences in how 
nicotine influences smoking across dependence severity levels. Considered together, these 
results indicate that smokers across dependence severity levels share a preference for higher 
over lower nicotine doses and experience a common profile of subjective effects from 
smoking. Where differences by dependence severity appear to come into play is in how 
those shared effects translate into demand intensity and associated urges. Whether this is 
attributable to individual differences in self-regulatory capabilities or some other system that 
governs demand intensity and associated smoking desire/urges was not examined in the 
present study but is a topic that merits further investigation (Bickel et al., 2007, 2016). At a 
practical level, the present results suggest that targeting interventions to more effectively 
reduce intensity of demand and associated urges will be important to improving cessation 
outcomes among more severely dependent smokers (MacKillop et al., 2016; O’Connor et 
al., 2016).
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Potential limitations of the present study are that (a) this is a secondary analysis of data 
collected to test other hypotheses and thus did not include dependent measures potentially 
relevant to elucidating processes underpinning differences between smokers of different 
dependence severity levels, (b) the population consisted exclusively of smokers with other 
co-morbid conditions potentially limiting generalizability to the general population of 
smokers, (c) only acute exposure to the cigarettes was examined leaving unanswered 
whether results will generalize to extended exposure, and (d) the study was conducted under 
double blind conditions leaving unanswered how these same populations would respond 
under un-blinded conditions more representative of naturalistic settings. These limitations 
notwithstanding, the present study helps address the important regulatory question of 
whether dependence severity will moderate response to a policy reducing the nicotine 
content of cigarettes, and provides new knowledge on potential differences in how nicotine 
influences smoking among more versus less dependent smokers.
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Results from the Cigarette Purchase Task simulating demand for cigarette smoking at 
escalating prices. The upper panel shows results from smokers categorized as mildly (scores 
= 0–2), moderately (score = 3), and highly (score = 4–6) dependent on the Heaviness of 
Smoking Index (HSI). Data points represent means for the three dependence severity levels 
at escalating prices averaging across participants and cigarette nicotine content doses (0.4, 
2.4, 5.2, 15.8 mg/g). The lower panel shows results by cigarette nicotine content dose; data 
points represent means at escalating prices for each dose averaging across participants and 
dependence-severity levels. Shaded areas represent 95% CIs in the best-fit lines. Data were 
collected from March 23, 2015, through April 25, 2016 at University of Vermont, Brown 
University, and Johns Hopkins University School of Medicine.
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Time-course of mean ratings on the Minnesota Tobacco Withdrawal Scale (MTWS) Desire-
to-Smoke item by Heaviness of Smoking Index (HSI) severity category with results from 
mildly, moderately, and highly dependent smokers shown in the left, center, and right-most 
panels. Error bars represent ± 1 SEM. Data were collected from March 23, 2015, through 
April 25, 2016 at University of Vermont, Brown University, and Johns Hopkins University 
School of Medicine.
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Upper panel: time-course of mean ratings on the brief Questionnaire of Smoking Urges 
(QSU) Factor 1 Scale with results from mildly, moderately, and highly dependent smokers 
shown in the left, center, and right-most panels. Error bars represent ± 1 SEM. Lower panel: 
time-course of mean ratings on the brief Questionnaire of Smoking Urges (QSU) Factor 2 
Scale with results from mildly, moderately, and highly dependent smokers shown in the left, 
center, and right-most panels. Error bars represent ± 1 SEM. Data were collected from 
March 23, 2015, through April 25, 2016 at University of Vermont, Brown University, and 
Johns Hopkins University School of Medicine.
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Effects of varying nicotine content level on mean maximum flow rate (mL/s) by Heaviness 
of Smoking Index (HSI) severity category with results from mildly, moderately, and highly 
dependent smokers shown in the left, center, and right-most panels. Maximum flow rate was 
measured using the Clinical Research Support System (CReSS, Lee et al., 2003). Error bars 
represent ± 1 SEM. Data were collected from March 23, 2015, through April 25, 2016 at 
University of Vermont, Brown University, and Johns Hopkins University School of 
Medicine.
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Table 3
Percent of choices for the lower dose in concurrent testing of the 0.4 versus 15.8 mg/g nicotine doses available 
at different response costs.
Percent of choices (mean ± SEM)
0.4 mg/g 15.8 mg/g
Overall 60.17 ± 2.98 39.83 ± 2.98
HSI mild 61.86 ± 4.29 38.14 ± 4.29
HSI moderate 60.72 ± 4.39 39.28 ± 4.39
HSI high 57.93 ± 4.42 42.07 ± 4.42
Tabled values represent least square means (± SEM). The 0.4 and 15.8 mg/g nicotine doses were concurrently available with the lower dose always 
available at 10 mouse clicks and higher dose available on a progressive ratio schedule (10, 160, 320, 640, 1280, 2400, 3600, 4800, 6000, 7200, and 
8400). Means in the upper row are collapsed across all participants, while those in all other rows are collapsed across only participants within the 
level of dependence severity indicated. There was a significant preference for the lower over the higher dose. There was no significant effect of 
dependence severity as preference for the lower dose was discernible across mildly (scores = 0–2), moderately (scores = 3), and highly (scores = 4–
6) dependent participants. Data were collected from March 23, 2015, through April 25, 2016 at University of Vermont, Brown University, and 
Johns Hopkins University School of Medicine.





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Prev Med. Author manuscript; available in PMC 2019 September 17.
